Almirall SA · BME:ALM

Almirall SA — FY2008 Earnings Presentation

44 slides from Almirall SA's earnings presentation, March 2009

  1. Slide 1: 2008 Full Year Results

    2008 Full Year Results March 2009

  2. Slide 2: Disclaimer

    Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptio

  3. Slide 3: 2008: A growth year for Almirall (I)

    2008: A growth year for Almirall (I) • Strong financial results. • Yearly financial targets achieved. • Performance in line with guidance and market consensus: - Net Sales: € 902,8 MM (+13,9%) Total Revenue € 1,056 Bn - Other Income: € 153,1 MM (+22,6%) (+15,1%) - R&D: € 139,3 MM (+14,1%) - EBITDA:

  4. Slide 4: 2008: A growth year for Almirall (II)

    2008: A growth year for Almirall (II) • Solid evolution of current portfolio, higher weight of international sales. • 2007 acquisitions fully integrated, synergies achieved. • International expansion furthered (four new affiliates). • Two important license-in agreements: sitagliptin (from MSD) and a

  5. Slide 5: Almirall since IPO: Consistency with strategic goals

    Almirall since IPO: Consistency with strategic goals 2006 2007 2008 ƒ Defend leadership position in Spain: - Net sales 517,1 521,3 534,0 - Headcount1 791 799 814 - Market share2 5,8% 5,6% 5.5% ƒ International expansion: - Affiliates sales 161,0 186,4 275,1 - License out / Corporate 79,9 84,8 93,6 -

  6. Slide 6: 2008 Financial Highlights

    2008 Financial Highlights Key financial data Net sales: € 902,8 MM (+13,9%) Total Revenue Other Income: € 153,1 MM (+22,6%) € 1,056 Bn (+15,1%) R&D: € 139,3 MM (+14,1%) EBITDA: € 230,0 MM (+35,0%) Net Income: € 136,1 MM (+3,8%) Normalized Net Income: € 142,5 MM (+5,8%) EPS: € 0,82 (+3,8%) Net Debt:

  7. Slide 7: EBITDA growth driven by sales of new businesses, cost containment and Other Income

    EBITDA growth driven by Sales of new businesses, costs and OPEX containment and Other Income from partners offsetting increased R&D. (€ Million) Key Takeaways • Strong growth in affiliates, steady growth in Spain, Sales up 13,9% 5% +3 • Improved Gross Profit (1,9pp on sales). 230,0 • R&D increase re

  8. Slide 8: Strong growth in affiliates, steady growth in Spain

    Strong growth in affiliates, steady growth in Spain (€ Million) Key Takeaways 792,5 902,8 • Strong growth in affiliates (+47,6%) driven by Germany, United + 13,9% 33,1 Kingdom and new 18,7 60,5 66,1 businesses, steady 275,1 growth in Spain (+2,4%) 186,4 • Price erosion in Spain below 1% (application

  9. Slide 9: Other Income increase linked to contributions to development and milestones

    Other Income increase linked to contributions to development and milestones from partners (€ Million) Key Takeaways % 2,6 +2 153,1 • Contributions to development 124,9 have increased significantly due mainly to AB Phase III (ACCLAIM studies). • Various payments linked to AB milestones and almotripta

  10. Slide 10: Positive Gross Margin and Expenses Evolution

    Positive Gross Margin and Expenses Evolution (€ Million) Gross Profit Evolution (Absolute and % over sales) Headlines and key drivers Gross Profit: Significant improvement (1,9pp on 61,2% 63,1% sales) % 7,5 +1 ificant nt • Miscellaneous costs savings (including import n e Sig ovem im p r of some raw

  11. Slide 11: Income Statement

    Income Statement € Million 2008 2007 % variation Strong growth in affiliates, Net Sales 902,8 792,5 13,9% steady growth in Spain. Gross Profit 569,4 484,6 17,5% % of sales 63,1% 61,2% Significant improvement Other Incom e 153,1 124,9 22,6% due to favourable product R&D -139,3 -122,0 14,1% mix and mi

  12. Slide 12: Almirall: Solid underlying P&L

    Almirall: Solid underlying P&L Positive evolution of strong fundamentals € MM 2006 2007 2008 Net Sales 758,0 792,5 902,8 Gross Margin 62,6% 61,2% 63,1% R&D 11,4% 15,4% 15,4% SG&A (w/o depreciation) 46,9% 42,2% 41,6% EBITDA 19,0% 21,5% 25,5% 12

  13. Slide 13: Solid balance sheet with further leverage potential

    Solid balance sheet with further leverage potential Balance Sheet % € Million 2008 2007 of BS Increase in depreciation due to new businesses (€ Goodw ill 273,5 19,6% 274,3 29 MM). Intangible assets 342,7 24,5% 383,4 Property, plant and equipment 175,7 12,6% 179,3 Key Takeaways Financial assets 3,9 0

  14. Slide 14: Strong cash flow generation

    Strong cash flow generation € 233,1 MM Cash Flow generation from Operating Activities in 2008 Cash Flow Figures € Million 2008 2007 Impact of 2007 acquisitions. Profit Before Tax 144,7 129,2 Depreciation and amortisation 63,3 36,0 Improvement of working Change in w orking capital 16,2 -26,8 capital

  15. Slide 15: Strong and steady Cash Flow generation

    Strong and steady Cash Flow generation 233,1 2008 2007 Acquisitions 218,8 (Hermal & Shire’s portfolio) 179 2007 -352,2 164,1 2006 191,9 -400 -300 -200 -100 0 100 200 300 Free Cash Flow Operating Free Cash Flow 15

  16. Slide 16: 2008 Operations Highlights

    2008 Operations Highlights • Sales increase (+13,9%) led by International Sales (+36%). • International Sales driven by UK and Germany. • Solid performance of Top-10 products (+2,1%), driven by Esertia, Parapres, Prevencor and Opiren. • 2007 acquisitions fully integrated, rolling out of derma portfo

  17. Slide 17: New Licensed Products in 2008

    New Licensed Products in 2008 Tesavel® (sitagliptin) Astucor® (amlodipine + atorvastatin) • New type 2 diabetes medicine that • New medicine that reduces the risk of addresses glycemic control. non-fatal myocardium infarction and fatal coronary disease by 53% in high • Co-marketing agreement with Me

  18. Slide 18: Sales by Region and Business

    Sales by Region and Business Net Sales breakdown by Geographic Area Net Sales breakdown by Distribution Channel € Million % € Million % 2008 2007 2008 2007 Variation Variation Spain 534,0 521,3 2,4% Own sales Network 534,0 521,3 2,4% (within Spain) Europe & Middle East 269,0 178,6 50,6% Own sales Ne

  19. Slide 19: Top 10 Products Sales

    Top 10 Products Sales Net Sales by PRODUCT % € Million 2008 2007 % of Sales Variation Prevencor (atorvastatin) 104,8 92,8 12,9% 11,6% Ebastine 100,7 100,4 0,2% 11,1% Plusvent 59,7 63,0 -5,3% 6,6% (salmeterol & fluticasone) Esertia (escitalopram) 55,6 47,3 17,4% 6,1% € 561M Aceclofenac 50,0 52,7 € 54

  20. Slide 20: Sales by Therapeutic Area

    Sales by Therapeutic Area Net Sales by Therapeutic Area € Million % 2008 2007 % of Sales Variation Cardiovascular 176,4 162,0 8,9% 19,5% CNS 172,7 172,6 0,1% 19,1% Respiratory 171,8 176,2 -2,5% 19,0% Digestive 139,7 128,4 8,8% 15,5% Dermatology 102,8 29,3 250,9% 11,4% Osteomuscular 82,1 78,3 4,8% 9,

  21. Slide 21: Factors that will contribute to sustain the base business until 2011-12

    Factors that will contribute to sustain the base business until 2011-12 9 Solid, branded, patented and well balanced product portfolio. 9 Current portfolio single digit top line sales evolution expected for 2009 and 2010 (excluding new Corporate Development projects). 9 Increased dermatology area pr

  22. Slide 22: Trends in the Spanish pharma market

    Trends in the Spanish pharma market Generic market evolution Market trends 100% 94,1% 93,4% 93,5% Spanish Market 80% (Sales 000€) 8.716 9.250 10.019 10.459 60% 2005 2006 2007 2008 Growth (in values) +5,7% +6,1% +8,3% +4,4% 40% 20% Almirall (Sales 000€) 14,4% 10,7% 6,6% 13,3% 5,9% 6,5% 531 539 558 57

  23. Slide 23: R&D Update (I)

    R&D Update (I) Aclidinium bromide Monotherapy • AB showed to improve lung function and was well tolerated in the Phase III trials with a desirable risk benefit profile. • Meeting with FDA held in March. • Regulatory interactions ongoing in EU. • New clinical programme ready to go following regulator

  24. Slide 24: R&D Update (II)

    R&D Update (II) Aclidinium bromide + Formoterol • Phase IIb programme ongoing: – Results to date confirm additive effects. – Further studies to start immediately. Aclidinium bromide + ICS • Further definition of this programme following regulatory authorities interactions about mono programme. 24

  25. Slide 25: R&D Update (III)

    R&D Update (III) OD LABA • LAS100977 progressing very well: – Two phase IIa studies in asthma completed with excellent results: ƒ Multiple dose results confirm efficacy and safety profile seen in single dose study. – One study ongoing, results March / April. – Aim to present data at ATS 2010. – Firs

  26. Slide 26: R&D Update (IV)

    R&D Update (IV) Rest of Pipeline • LAS186323 (DHODH inhibitor for RA / MS) progressing well: – Single dose FIM completed with torelability. – Backup (LAS187247) in pre-clinical development. – Licensing options under evaluation. • Dermatology: – LAS41001, retinoid for rosacea filed. – One formulation

  27. Slide 27: A pipeline with significant upside

    Auto-immune A pipeline with significant upside Respiratory Dermatology Pipeline Status (the right end of each bar represents status of development as of March 6th ) Expected filing Preclinical Ph I Ph II Ph III Registration date Aclidinium bromide (AB) (anti-muscarinic) COPD Under review AB + Formot

  28. Slide 28: Targets and Outlook

    Targets 2008 and Outlook Guidance 2009 28

  29. Slide 29: R&D Outlook 2009

    R&D Outlook 2009 Expected newsflow Aclidinium bromide • March/April’09 – Market update after regulatory interactions (US and Europe). • May’09 – ATS – Further details on aclidinium bromide’s Phase III data. • Sep.’09 – ERS – Further details on aclidinium bromide’s Phase III data. • During 2009, star

  30. Slide 30: Financial Outlook 2009

    Financial Outlook 2009 Financial guidance • 2009 P&L perspectives : − Expected single digit growth in sales, EBITDA and Normalised Net Income. − Pay-out policy to be maintained at 35-40% (unless capital discipline and/or business requirements dictate otherwise). 30

  31. Slide 31: Corporate Development Outlook 2009

    Corporate Development Outlook 2009 Priorities for 2009 • Partnering AB in key geographies. • Partnering of OD LABA (LAS100977). • Pursuing new license-in opportunities. • Continue to evaluate selected acquisitions. 31

  32. Slide 32: Almirall – Sources of value creation and strategic goals

    Almirall – Sources of value creation and strategic goals Strategic position ƒ R&D driven, focus on innovation. ƒ #1 Spanish pharma, #1 dermatology pharma in Germany and #7 across Europe. ƒ Diversified product portfolio with low STRATEGIC GOALS exposure to price/volume erosion in Spain until 2011/12.

  33. Slide 33: About Almirall: R&D highlights

    About Almirall R&D highlights 33 Dr Per Olof Andersson, CSO

  34. Slide 34: Almirall as investment case

    Almirall as investment case Solid fundamentals focused on long term value creation Combining a well-established business … …with significant upside from pipeline ƒ Branded, patented balanced ƒ Broadest and deepest pipeline in company history. portfolio. ƒ Spanish leadership. ƒ Aclidinium bromide (AB

  35. Slide 35: Almirall – Focus on growth and value creation

    Almirall – Focus on growth and value creation Founded 1943 Almirall aims to become a reference mid-cap R&D–driven pharma player by strengthening its Pan-European presence and expanding its IPO 2007 global footprint through organic and non-organic growth Sales guidance 2009: single digit growth vs. 2

  36. Slide 36: Almirall's business model

    Almirall’s business model A successful combination of R&D and corporate development Almirall has been a successful Direct sales by Almirall in-licensor of major pharma through 11 affiliates products in Spain and 2008 Sales throughout Europe € 902,8 Mill. Some examples are: c. 45% c. 55% Spain Atorva

  37. Slide 37: A fully integrated company with global reach

    A fully integrated company with global reach R&D Centres in 11 Affiliates in Spain and Europe and Latin Germany America Our products are Manufacturing present in the five Plants in Spain continents (more and Germany than 70 countries) 37

  38. Slide 38: A stable, branded and well-balanced product portfolio

    A stable, branded and well-balanced product portfolio Interna- € Million 2008 % Spain tional Prevencor (atorvastatine) 104,8 12 9 Ebastine 100,7 11 9 9 9Diversified risk across Plusvent (salmeterol & fluticasone) 59,7 7 9 therapies, geographies, Esertia (escitalopram) 55,6 6 9 product sales and sour

  39. Slide 39: Strong track record in pursuing opportunities

    Strong track record in pursuing opportunities 2005 2006 2007 2008 2009 Moving Forward Hermal GmbH • Roll out of Derma pipeline and portfolio. EU Rights for Tesavel® • Sativex opportunity (Spasticity and Sativex (sitagliptin) in from GW Spain Cancer pain). (ex-UK) from MSD Divestment of 13 non- • Acl

  40. Slide 40: Genuair: superior inhalation device

    Genuair®: superior inhalation device Designed for compliance with global regulatory standards (FDA, EMEA, Japan) What makes our inhaler different? 9A preloaded device. 9A novel inhalation system which consists of only 2 steps: press and inhale. 9A unique device with three feedback to the patient: a

  41. Slide 41: Proven R&D track record and competitive capabilities

    Proven R&D track record and competitive capabilities A focused strategy that balances risk and reward International R&D capabilities with proven track record • R&D expense above 15% of sales. • 3 R&D centers in Spain and Germany with c. 600 staff. • 40 years of R&D expertise, 7 international product

  42. Slide 42: Our history

    Our history • Opening of affiliates in the United Kingdom-Ireland, Austria, Switzerland and Poland. • Co-marketing agreement with MSD for Tesavel® in Spain. 2008 • Co-marketing agreement with Pfizer for Astucor® in Spain. • IPO in June. 2007 • Acquisition of Hermal, a • Opening of a new R&D Centre i

  43. Slide 43: For further information, please contact

    For further information, please contact: Jordi Molina, Head of Investor Relations Ph. +34 93 291 3087 jordi.molina@almirall.com Or visit our website: www.almirall.com 43

  44. Slide 44: Almirall

    iA . (4 Almirall Solutions thinking of you

Almirall — FY2008 Earnings Presentation on 6ix